A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluate the Efficacy and Safety of Oral Administration of Different Doses of SY-009 Capsule in Patients With T2DM for 12 Weeks
Latest Information Update: 08 May 2024
At a glance
- Drugs SY 009 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Suzhou Yabao Pharmaceutical
Most Recent Events
- 24 Jun 2022 New trial record